Latest & greatest articles for screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for screening

181. Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up (Abstract)

Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up We assessed the effect of screening in the European Randomized study of Screening for Prostate Cancer (ERSPC) Rotterdam pilot 1 study cohort with men randomized in 1991-1992. A total of 1134 men were randomized on a 1:1 basis to a screening (S) and control (C) arm after prostate-specific antigen (PSA) testing (PSA ≥10.0ng/ml was excluded from randomization). Further PSA testing was offered to all men in the S-arm (...) with 4-yr intervals starting at age 55yr and screened up to the age of 74yr. Overall, a PSA level of ≥3.0ng/ml triggered biopsy. At time of analysis, 63% of men had died. Overall relative risk of metastatic (M+) disease and prostate cancer (PCa) death was 0.46 (95% confidence interval [CI]: 0.19-1.11) and 0.48 (95% CI: 0.17-1.36), respectively, in favor of screening. This ERSPC Rotterdam pilot 1 study cohort, screened in a period without noteworthy contamination, shows that PSA-based screening could

2019 EvidenceUpdates

182. Bowel screening

Bowel screening Bowel screening - NICE CKS Share Bowel screening: Summary The NHS Bowel Cancer Screening Programme aims to identify bowel cancer at an early stage when treatment is more likely to be successful. In Scotland, screening is offered every two years to people aged 50–74 years. In England, Wales and Northern Ireland screening is offered every two years to people aged 60–74 years. In some areas of England, one-off flexible sigmoidoscopy (Bowelscope) screening is offered to people aged (...) 55 years. In 2016 the UK National Screening Committee recommended that faecal immunochemical testing (FIT) should replace guaiac faecal occult blood testing (gFOBt) as the primary screening test for bowel cancer screening. FIT replaced gFOBt in Scotland in 2017 and will be introduced in England and Wales in 2019, gFOBt remains the primary test in Northern Ireland. An invitation letter followed by a faecal occult blood test kit is sent to participants’ home address. FIT testing — the end of a test

2019 NICE Clinical Knowledge Summaries

183. Cost-effectiveness of community-based screening and treatment of moderate acute malnutrition in Mali. Full Text available with Trip Pro

Cost-effectiveness of community-based screening and treatment of moderate acute malnutrition in Mali. Moderate acute malnutrition (MAM) causes substantial child morbidity and mortality, accounting for 4.4% of deaths and 6.0% of disability-adjusted life years (DALY) lost among children under 5 each year. There is growing consensus on the need to provide appropriate treatment of MAM, both to reduce associated morbidity and mortality and to halt its progression to severe acute malnutrition. We

2019 BMJ global health Controlled trial quality: uncertain

184. Human Immunodeficiency Virus (HIV) Infection: Screening

Human Immunodeficiency Virus (HIV) Infection: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Pregnant persons The USPSTF recommends that clinicians screen for HIV infection in all pregnant persons, including those who present in labor or at delivery whose HIV status is unknown. A Adolescents and adults aged 15 to 65 years The USPSTF recommends that clinicians screen for HIV infection in adolescents (...) and adults aged 15 to 65 years. Younger adolescents and older adults who are at increased risk of infection should also be screened. A View the Clinical Summary in Population Adolescents and adults aged 15 to 65 years Pregnant Persons Recommendation Screen for HIV infection. Grade: A Screen for HIV infection. Grade: A Risk Assessment Although all adolescents and adults aged 15 to 65 years should be screened, there are a number of risk factors that increase risk. Among adolescents younger than 15 years

2019 U.S. Preventive Services Task Force

185. Elevated Blood Lead Levels in Children and Pregnant Women: Screening

Elevated Blood Lead Levels in Children and Pregnant Women: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Pregnant persons The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for elevated blood lead levels in asymptomatic pregnant persons. I Children 5 years and younger The USPSTF concludes that the current evidence is insufficient (...) to assess the balance of benefits and harms of screening for elevated blood lead levels in asymptomatic children. I View the Clinical Summary in Population Children 5 years and younger and pregnant persons Recommendation No recommendation. Grade: I (insufficient evidence) Screening Tests Elevated blood lead levels can be detected by measuring capillary or venous blood lead levels. Capillary blood testing is recommended for initial screening. Patients with positive screening results from capillary blood

2019 U.S. Preventive Services Task Force

186. Abdominal Aortic Aneurysm: Screening

Abdominal Aortic Aneurysm: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Men aged 65 to 75 years who have ever smoked The USPSTF recommends 1-time screening for abdominal aortic aneurysm (AAA) with ultrasonography in men aged 65 to 75 years who have ever smoked. B Men aged 65 to 75 years who have never smoked The USPSTF recommends that clinicians selectively offer screening for AAA with ultrasonography (...) in men aged 65 to 75 years who have never smoked rather than routinely screening all men in this group. Evidence indicates that the net benefit of screening all men in this group is small. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the balance of benefits and harms on the basis of evidence relevant to the patient's medical history, family history, other risk factors, and personal values. C Women who have never smoked The USPSTF

2019 U.S. Preventive Services Task Force

187. Asymptomatic Bacteriuria in Adults: Screening

Asymptomatic Bacteriuria in Adults: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Pregnant persons The USPSTF recommends screening for asymptomatic bacteriuria using urine culture in pregnant persons. B Nonpregnant adults The USPSTF recommends against screening for asymptomatic bacteriuria in nonpregnant adults. D View the Clinical Summary in What does the USPSTF recommend? For pregnant persons: Grade B (...) Screen persons who are pregnant for asymptomatic bacteriuria with a urine culture. For nonpregnant adults: Grade D Do not screen adults who are not pregnant for asymptomatic bacteriuria. To whom does this recommendation apply? This applies to adults 18 years and older and pregnant persons of any age without signs and symptoms of a urinary tract infection. It does not apply to persons who have chronic medical or urinary tract conditions or are hospitalized or living in institutions such as nursing

2019 U.S. Preventive Services Task Force

188. Hepatitis B Virus Infection in Pregnant Women: Screening

Hepatitis B Virus Infection in Pregnant Women: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Pregnant women The USPSTF recommends screening for hepatitis B virus (HBV) infection in pregnant women at their first prenatal visit A View the Clinical Summary in Population Pregnant Persons Recommendation Screen for hepatitis B virus (HBV) infection. Grade: A Risk Assessment In the United States, new cases of HBV (...) among adults are largely transmitted through injection drug use or sexual intercourse, but most prevalent cases of HBV infection are chronic infections from exposure occurring in infancy or childhood. Another major risk factor for HBV infection is country of origin. In the United States, adults with HBV born in high-prevalence countries were commonly infected during childhood. In children, the primary source of infection is perinatal transmission at birth. Screening Tests The principal screening

2019 U.S. Preventive Services Task Force

189. Cell-free DNA to Screen for Single-Gene Disorders

Cell-free DNA to Screen for Single-Gene Disorders Cell-free DNA to Screen for Single-Gene Disorders | ACOG Clinical Guidance Journals & Publications Patient Education Topics Featured Clinical Topics Hi, Featured Clinical Topics Clinical Guidance Cell-free DNA to Screen for Single-Gene Disorders Practice Advisory February 2019 Jump to Resources Share By reading this page you agree to ACOG's Terms and Conditions. . The application of cell-free DNA technology for Rh disease and the current

2019 American College of Obstetricians and Gynecologists

190. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors Full Text available with Trip Pro

2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors 2019 ASCCP Risk-Based Management Consensus Guidelines for Ab... : Journal of Lower Genital Tract Disease ')} You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Your account has been temporarily locked Your account has been temporarily locked due to incorrect sign in attempts and will be automatically (...) in the development of these guidelines . The corresponding authors had final responsibility for the submission decision. The National Cancer Institute (including M.S. and N.W.) receives cervical screening results at reduced or no cost from commercial research partners (Qiagen, Roche, BD, MobileODT, Arbor Vita) for independent evaluations of screening methods and strategies. A.-B.M. is an advisory board member of Merck and GSK. R.S.G. is an ASCCP consultant of Inovio Pharmaceuticals DSMB. W.K.H. is connected

2019 American Society for Clinical Pathology

191. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. (Abstract)

Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. The Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC), the largest component of the European Randomized Study of Screening for Prostate Cancer (ERSPC), showed a smaller, nonsignificant reduction in prostate cancer-specific mortality by systematic prostate-specific antigen (PSA)-based screening compared with the overall ERSPC results. Nonsteroidal anti (...) -inflammatory drugs (NSAIDs) reduce inflammation and also PSA elevations due to intraprostatic inflammation.To explore whether NSAID usage modifies the effects of PSA-based screening on prostate cancer incidence and mortality.A cohort of 78 165 men from the FinRSPC were linked to a comprehensive national prescription database to obtain information on NSAID reimbursements prior to screening.Prostate cancer risk and mortality were compared between the FinRSPC screening arm and the control arm among NSAID

2018 European urology focus

192. Screening for Colorectal Cancer

Screening for Colorectal Cancer CLINICAL PRACTICE GUIDELINE Clinical Practice Guideline on Screening for Colorectal Cancer in Individuals With a Family History of Nonhereditary Colorectal Cancer or Adenoma: The Canadian Association of Gastroenterology Banff Consensus Desmond Leddin, 1,2, * David A. Lieberman, 3, * Frances Tse, 4 Alan N. Barkun, 5 Ahmed M. Abou-Setta, 6 John K. Marshall, 4 N. Jewel Samadder, 7 Harminder Singh, 6,8 Jennifer J. Telford, 9 Jill Tinmouth, 10 Anna N. Wilkinson, 11 (...) Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada BACKGROUND & AIMS: A family history (FH) of colorectal cancer (CRC) increases the risk of developing CRC. These consensus recommendations developed by the Canadian As- sociation of Gastroenterology and endorsed by the American Gastroenterological Association, aim to provide guidance on screening these high-risk individuals. METHODS: Multiple parallel systematic review streams, informed by 10 literature searches, assembled

2018 Canadian Association of Gastroenterology

193. Emergent Large Vessel Occlusion Screen Is an Ideal Prehospital Scale to Avoid Missing Endovascular Therapy in Acute Stroke Full Text available with Trip Pro

Emergent Large Vessel Occlusion Screen Is an Ideal Prehospital Scale to Avoid Missing Endovascular Therapy in Acute Stroke Background and Purpose- The strong evidence of endovascular therapy in acute ischemic stroke patients with large vessel occlusion (LVO) is revealed. Such patients are required to direct transport to the hospital capable of endovascular therapy. There are several prehospital scales available for paramedics to predict LVO. However, they are time consuming, and several of them (...) include factors caused by other types than LVO. Therefore, we need a fast, simple, and reliable prehospital scale for LVO. Methods- We developed a new prehospital stroke scale, emergent large vessel occlusion (ELVO) screen, for paramedics to predict LVO. The study was prospectively performed by multistroke centers. When paramedics referred to stroke center to accept suspected stroke patients, we obtain the following information over the telephone. ELVO screen was designed focusing on cortical symptoms

2018 EvidenceUpdates

194. Recommendations on screening for breast cancer in women 40-74 years of age who are not at increased risk

Recommendations on screening for breast cancer in women 40-74 years of age who are not at increased risk Recommendations on screening for breast cancer in women aged 40–74 years who are not at increased risk for breast cancer | CMAJ Main menu User menu Search Search for this keyword Search for this keyword Guideline Recommendations on screening for breast cancer in women aged 40–74 years who are not at increased risk for breast cancer Scott Klarenbach , Nicki Sims-Jones , Gabriela Lewin (...) POINTS Low-certainty evidence indicates that screening for breast cancer with mammography results in a modest reduction in breast cancer mortality for women aged 40 to 74 years; the absolute benefit is lowest for women younger than 50 years. Screening may lead to overdiagnosis, resulting in unnecessary treatment of cancer that would not have caused harm in a woman’s lifetime and false-positive results that can lead to both physical and psychological consequences; overdiagnosis and false-positives

2018 Canadian Task Force on Preventive Health Care

195. Canadian Cardiovascular Society/Canadian Heart Rhythm Society Joint Position Statement on the Cardiovascular Screening of Competitive Athletes Full Text available with Trip Pro

Canadian Cardiovascular Society/Canadian Heart Rhythm Society Joint Position Statement on the Cardiovascular Screening of Competitive Athletes Canadian Cardiovascular Society/Canadian Heart Rhythm Society Joint Position Statement on the Cardiovascular Screening of Competitive Athletes - Canadian Journal of Cardiology Email/Username: Password: Remember me Search Terms Search within Search Share this page Access provided by Volume 35, Issue 1, Pages 1–11 Canadian Cardiovascular Society/Canadian (...) Heart Rhythm Society Joint Position Statement on the Cardiovascular Screening of Competitive Athletes Primary Panel (CCS Sport Group) : , x Amer M. Johri Affiliations Queen’s University, Kingston, Ontario, Canada Correspondence Corresponding author: Dr Amer M. Johri, MD, MSc, FRCPC, FASE, Queen’s University, Department of Medicine, Division of Cardiology, CINQ, 76 Stuart St, FAPC 3, Kingston, Ontario K7L 2V7, Canada. Tel.: +1-613-549-6666; fax: +1-613-533-6695. , MD, MSc, FRCPC, FASE (Co-chair

2018 Canadian Cardiovascular Society

196. Clinical relevance of screening checklists for detecting cancer predisposition syndromes in Asian childhood tumours Full Text available with Trip Pro

Clinical relevance of screening checklists for detecting cancer predisposition syndromes in Asian childhood tumours Assessment of cancer predisposition syndromes (CPS) in childhood tumours is challenging to paediatric oncologists due to inconsistent recognizable clinical phenotypes and family histories, especially in cohorts with unknown prevalence of germline mutations. Screening checklists were developed to facilitate CPS detection in paediatric patients; however, their clinical value have (...) yet been validated. Our study aims to assess the utility of clinical screening checklists validated by genetic sequencing in an Asian cohort of childhood tumours. We evaluated 102 patients under age 18 years recruited over a period of 31 months. Patient records were reviewed against two published checklists and germline mutations in 100 cancer-associated genes were profiled through a combination of whole-exome sequencing and multiplex ligation-dependent probe amplification on blood-derived genomic

2018 NPJ genomic medicine

197. Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. Excessive alcohol use is one of the most common causes of premature mortality in the United States. From 2006 to 2010, an estimated 88 000 alcohol-attributable deaths occurred annually in the United States, caused by both acute conditions (eg, injuries from motor vehicle collisions) and chronic conditions (eg, alcoholic liver (...) disease). Alcohol use during pregnancy is also one of the major preventable causes of birth defects and developmental disabilities.To update the US Preventive Services Task Force (USPSTF) 2013 recommendation on screening for unhealthy alcohol use in primary care settings.The USPSTF commissioned a review of the evidence on the effectiveness of screening to reduce unhealthy alcohol use (defined as a spectrum of behaviors, from risky drinking to alcohol use disorder, that result in increased risk

2018 JAMA

198. Dental radiograph as an opportunistic screening tool for a colorectal cancer syndrome (CAT#3342)

Dental radiograph as an opportunistic screening tool for a colorectal cancer syndrome (CAT#3342) UTCAT3342, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Dental radiograph as an opportunistic screening tool for a colorectal cancer syndrome Clinical Question Does dental radiograph serve as an opportunistic screening tool for early detection of extraintestinal manifestations of Familial Adenomatous Polyposis (FAP (...) ) in children and adults? Clinical Bottom Line Incidental findings on dental radiographs could serve as screening tools for systemic diseases and syndromes. The attention should be raised when gene mutation, congenitally diseases or familial colorectal cancer are reported by patients during the medical history questionnaire. For patients with risk of FAP, the Dental panoramic radiographic score (DPRS) is inexpensive, and reinforce the referral for the further clinical investigation, gene mapping

2018 UTHSCSA Dental School CAT Library

199. Leading Women's Health Care Groups Issue Joint Statement on USPSTF Final Cervical Cancer Screening Recommendations

Leading Women's Health Care Groups Issue Joint Statement on USPSTF Final Cervical Cancer Screening Recommendations

2018 Society of Gynecologic Oncology

200. Evaluating cognitive screening instruments with the "likelihood to be diagnosed or misdiagnosed" measure (Abstract)

Evaluating cognitive screening instruments with the "likelihood to be diagnosed or misdiagnosed" measure To calculate "number needed to diagnose" (NND), "number needed to predict" (NNP), and "number needed to misdiagnose" (NNM) for cognitive screening instruments which are commonly used in suspected dementia and mild cognitive impairment, and from these to calculate a "likelihood to be diagnosed or misdiagnosed" (LDM) metric as the ratio of NNM to either NND or NNP.Datasets from pragmatic (...) diagnostic test accuracy studies examining four commonly used cognitive screening instruments (Mini-Mental State Examination, MMSE; Montreal Cognitive Assessment, MoCA; Mini-Addenbrooke's Cognitive Examination, MACE; Six-item Cognitive Impairment Test, 6CIT) were analysed to calculate NND, NNP, and NNM, and from these derive values for LDM.Although all the tests had low NND and NNP as desired, NNM was also low. Hence, only MMSE and 6CIT achieved LDM > 1 for dementia diagnosis, and only MACE and 6CIT had

2018 EvidenceUpdates